Table 2 Experiment 1: losses after intravenous injection of Biferonex®, relative concentrations and actual doses after direct subcutaneous injection at various dose levels
From: Biases affecting injected doses of an experimental drug during clinical trials
Dose level [MIU] (Biferonex® HSA-free) | Losses after intravenous injection | Relative concentration (direct subcutaneous injection) | Actual dose [MIU] (direct subcutaneous injection) | |||
|---|---|---|---|---|---|---|
Median | Range | Median | Range | Median | Range | |
0.5 | −4.3 % | 22.3 % | 93 % | 34 % | 0.57 | 0.13 |
1.0 | −10.6 % | 31.9 % | 115 % | 29 % | 1.10 | 0.02 |
4.0 | −7.3 % | 15.6 % | 94 % | 16 % | 4.38 | 0.10 |